BNET Industries
Pharma Industry
Industry news and insights by David Hamilton
- Get Pharma Industry via:
- Mobile
- RSS Feed
- Email Alerts
Byetta's Secret to Success: Pose as a Diet Drug
Eli Lilly's diabetes drug is expensive, has nasty side effects, and now it's been linked to six fatalities. So why are sales so high?... Continued »
Submit your own BNET Pharma Insights
Top 10 Weirdest Pharma Stories of the Month
Sometimes I come across items that aren’t important enough to count as news but are nonetheless too strange to ignore. Thus, I give you the top 10 weirdest drug stories for August:
The connection between O.J. and Preparation H. Ever wonder why the orange juice in your fridge lasts so long? Thank this guy: Dr. Robert […]
...- Bayer Faces PR Damage Over Mass Bee Deaths
- Behind the Byetta Crisis: Is This Drug Really All That and a Bag of (Fat-Free) Chips?
- Abbott Labs’ “Position of Strength” May Not Be as Strong as It Looks
- What Lilly Learned From Steak n Shake: A Q&A on Cymbalta
- Noven and P&G Try “Viagra for Women” Despite History of Failure
- More Pharma Insights
Pharma Articles
-
Life, Death and New Drugs
Amylin's recent woes with its new diabetes drug, Byettasix people have died, possibly as a result of taking the drugraises a crucial question that has long vexed companies and patients about the medications we take for what ails us. What is an acceptable trade-off between drugs...
-
Merck's Charm Offensive for Gardasil
Mike Huckman submits: In the current monster-sized issue of Vogue, my producer, Ruth, while killing time on the Delta shuttle on our way from New York to Boston for a shoot this week, uncovered a blogworthy story buried in the hundreds and hundreds and hundreds of pages of fashion...
-
SL Pharma Wins SFDA Approval for New Drug and a Clinical Trial
ChinaBio Today submits: Beijing SL Pharmaceutical Co. Ltd. (SZSE: 002038) received SFDA approval to begin producing a hepatitis drug and a second SFDA authorization to begin clinical trials of drug for male infertility. Adefovir dipivoxil, the drug newly approved for marketing, is aimed at hepatitis B. It is currently...
-
Novartis Takes $235 Million Charge After Stopping Trial
ZURICH (Reuters) - Novartis AG NOVN stopped development of its Aurograb treatment for bacterial infections after it showed a lack of efficacy in mid-stage trials, and said it would take a $235 million impairment charge. The Swiss drugmaker said on Friday the charge,...
-
Court Dismisses Lawsuit Against McKesson
(Reuters) - A federal judge has dismissed a case against McKesson Corp MCK that alleged the drug wholesaler of unlawful price-fixing, court documents showed on Friday. Judge Patti Saris granted the company's motion to dismiss, saying the plaintiffs, led by the New England...
-
Five Biopharma Companies Drop on Negative Drug News
Mike Huckman submits: Within a 12-hour period five biopharma companies revealed negative drug news that is sending their stocks lower -- in the case of Amylin Pharmaceuticals AMLN and Cell Genesys CEGE, much lower. After the closing bell Tuesday, Bristol-Myers Squibb BMY and Pfizer PFE announced a bloodclot drug...
-
Will You Look Back on Today as Your Greatest Missed Opportunity?
Dividends4Life submits: When most people hear the phrase "missed opportunities" they tend to reflect on past events and what could have been. By nature I am forward looking, so "missed opportunities" for me is the present and the future.At some point in the future will we look back on...
-
Pfizer Is Worth Another Look
Ockham Research submits: For shareholders of Pfizer, Inc. PFE stock, it has been a pretty barren decade. Like many large pharmaceutical stocks, Pfizer shares have done virtually nothing in years. Admittedly, the stock pays a generous dividend (6.5%+) which appears fairly secure. However, at some point, Pfizer is...
-
Amgen to Discontinue Discounts on Anemia Drug: Report
(Reuters) - Amgen Inc AMGN is halting some pricing practices that critics say were contributing to overuse of its flagship anemia drug Aranesp at a time of mounting concerns about the product's safety, the New York Times said. Amgen confirmed late on Wednesday...
-
Immtech Pharmaceuticals, Inc. F1Q09 (Qtr End 06/30/08) Earnings Call Transcript
Immtech Pharmaceuticals, Inc. IMM F1Q09 (Qtr End 06/30/08) Earnings Call Transcript
-
Wednesday Options Update: LEH, AMLN, XLE, NTAP, CLNE, HOS, DLTR, TEL, ESI
Rebecca Engmann Darst contributed to this report. Lehman Brothers LEH – A more positive tone for Lehman’s today has shares knocking on the door of the $15.00 mark having rallied by 6.3% so far Wednesday. Options volume puts Lehman’s on our scanner of most actively traded equity options today....
-
Amylin, Lilly: Another Case of a Panic Driven Sell-Off
A. Reza Saadat submits: On Tuesday August 26, Amylin AMLN and its partner Eli Lilly LLY announced that four patients had died while on diabetes treatment Byetta.Both Amylin (down 12%) and Lilly (down 1%) sold off in after hours following repeated headlines saying Byetta was responsible for the...
-
Drug Safety Updates For Elan, Biogen, Amylin, and Lilly
Mike Huckman submits: After the closing bell Monday, Eli Lilly LLY and Amylin Pharmaceuticals AMLN announced that they're going to hold a conference call for analysts and investors about their diabetes drug Byetta. Last week, the Food and Drug Administration revealed that six patients on the drug had to...
-
NICE Endorses Novartis Eye Drug Lucentis
LONDON (Reuters UK) - The healthcare cost-effectiveness watchdog NICE has recommended Novartis's pricey eye drug Lucentis, under a special scheme that will cap the cost of treatment to the state health service. The move, which follows a draft plan agreed last December, means the National...
-
Abbott Labs' "Position of Strength" May Not Be as Strong as It Looks
Figuring out whether Abbott Laboratories is firing on all cylinders or heading for a wall is a complicated business. On the one hand, the company announced it would lay off 1,000 employees in its diagnostics business. Abbott spokesperson Melissa Brotz said: We are taking this action...
-
AstraZeneca Begins Its Flu Campaign Season, and Pharma Donates to Candidates
Mike Huckman submits: Talk about timely direct-to-consumer advertising. Last week, I blogged about AstraZeneca's new ad campaign for FluMist and its tie-in with the back-to-school shopping season. Well, now the drugmaker is getting political. To coincide with the official start of the presidential campaign season and the Democratic National...
-
Tuesday Options Update: UNG, WYE, XLF, GE, AAPL, MRVL, FNM, MCRS, CLNE, CAKE,
Rebecca Engmann Darst contributed to this report. US Natural Gas Fund UNG – Here’s a trade that stuck out like a sore thumb to us today. We saw 16,000 call options in the April series trade at the 70 strike for a premium of 0.90. The volume represents 5% of...
-
Amylin Shares Gain Ground on Outlook for Byetta
Trader Mark submits: I've been stating for a while now that this market has changed character - even as the bear market hit us in the winter we were still able to find pockets of strength where buying breakouts were rewarded. However, at this time, instead of buying breakouts, the...
-
Largest Companies in the World
Hickey and Walters Bespoke submit: Below we highlight the 30 largest companies in the World by market cap ($). As shown, Exxon Mobil XOM is the top dog by about $70 billion. Exxon is trailed by another energy company, Petrochina PTR, then General Electric GE and Microsoft MSFT. ...
-
Akorn, Inc. Q2 2008 Earnings Call Transcript
Akorn, Inc. AKRX Q2 2008 Earnings Call Transcript
Top Companies
- Johnson & Johnson $190.6B
- Pfizer Inc. $136.7B
- Merck & Co. Inc. $89.7B
- Abbott Laboratories Inc. $79.7B
- Genentech Inc. $77.0B
- McKesson Corp. $92.9B
- Cardinal Health Inc. $86.8B
- AmerisourceBergen Corp. $66.0B
- Johnson & Johnson $61.0B
- Pfizer Inc. $48.4B
- Johnson & Johnson $10.5B
- Pfizer Inc. $8.1B
- Wyeth $4.6B
- Abbott Laboratories Inc. $3.6B
- Merck & Co. Inc. $3.2B
Top Rated
- Biotech's New Blockbusters -- Oh, Really?+37 votes
- Doctors vs. Drug Companies: Pharma is Winning -- So Far+35 votes
- Rating and Ranking "Stealth Pharmas"+33 votes
- Wyeth, Elan and Bapineuzumab -- How to Lie With (Drug) Statistics+31 votes
- Roche-Genentech: Desperation Is On the Rise+30 votes
- Pfizer Cuts a Deal -- No Bid for Ranbaxy+22 votes
- GSK Employees Really Love Their Boss's Book -- It's "Better Than Harvard"!+18 votes
- Takeda's Spree Peaks With Millennium Buy+17 votes
Recommended Sources
BNET Industries Blogroll
AboutPharma Industry
BNET Pharma provides daily industry news coverage and insights for managers and executives about the major manufacturers of pharmaceuticals and medicine. In addition to detailed company profiles, we bring you critical analysis on new alliances and partnerships, new patents and products, mergers and acquisitions, cost management, investments and deal flow, and a host of other important business issues.
